Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY20
Investor Presentation
Q4 FY19
Investor Presentation
Q3 FY19
Investor Presentation
Q2 FY19
Investor Presentation
Q1 FY19
Investor Presentation
Q4 FY18
Investor Presentation
Q3 FY18
Bliss GVS Pharma Ltd (BLISSGVS) is currently trading at 450.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries. The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa. Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations. Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum. Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.
Over the past 52 weeks, Bliss GVS Pharma Ltd has traded between a low of ₹118.35 and a high of ₹552.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bliss GVS Pharma Ltd has a market capitalization of approximately 4,889.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bliss GVS Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,889.19 Cr, Bliss GVS Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bliss GVS Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bliss GVS Pharma Ltd is 37.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The open offer price is ₹299.00 per equity share, as stated in the Draft Letter of Offer filed with SEBI.
The open offer is at ₹299 per share for up to 2,77,26,848 shares, representing 26.00% of Bliss GVS Pharma’s expanded voting share capital.
It is a mandatory open offer to acquire up to 2,77,26,848 equity shares (26.00% of expanded voting share capital) of Bliss GVS Pharma at ₹299 per share.
The stock surged after Anupam Rasayan announced a plan to acquire up to a 43.3% stake in Bliss GVS Pharma, triggering strong buying interest.
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries.
The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa.
Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations.
Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum.
Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,773 Cr
High Risk
37.0
37.2
8.7
4.1
552.90
118.35
Sales CAGR
Profit CAGR
ROE
ROCE
Open Offer
SBI Capital Markets submitted a Pre-Offer Advertisement and corrigendum (published 27-07-2026) for an Open Offer by Anupam Rasayan (with PAC) to acquire up to 2,77,26,848 shares (26%) of Bliss GVS Pharma.
Regulatory/Compliance Filing
SBI Capital Markets filed a Pre-Offer Advertisement and Corrigendum to the Detailed Public Statement for Bliss GVS Pharma Ltd regarding an Open Offer by Anupam Rasayan India Ltd (with PAC) to acquire up to 2,77,26,848 shares (26%).
Change in Directors/KMP
Bliss GVS Pharma Ltd: Mr. Sachin Saboo resigned as General Manager - Regulatory & Clinical (Senior Management). Resignation dated April 30, 2026; relieved effective close of business on July 24, 2026.
Change in Directors/KMP
Bliss GVS Pharma Ltd informed exchange that Mr. Sachin Saboo, General Manager - Regulatory & Clinical (Senior Management Personnel), resigned and was relieved effective close of business on July 24, 2026.
Regulatory/Compliance Filing
Bliss GVS Pharma published the Committee of Independent Directors' recommendation on the open offer by Anupam Rasayan India Ltd (with PAC) for 2,77,26,848 shares (26% EVSC) at INR 299/share; published on July 23, 2026.
Regulatory/Compliance Filing
Bliss GVS Pharma published the Committee of Independent Directors' recommendation on 23-07-2026 regarding the open offer by Anupam Rasayan India Ltd and Mates Visa Consultancy Pvt Ltd for 2,77,26,848 shares (26%) at INR 299 per share.
Bearish
3
Neutral
3
Bullish
8
Bearish
22
Neutral
3
Bullish
21
Bearish
19
Neutral
0
Bullish
13
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
975.00 | 5,527 Cr | 39.22 | 5.07 | 0.21 | 12.92 | 14.30 | 7.67 | ||
990.00 | 5,002 Cr | 245.70 | 3.88 | 0.00 | 2.11 | 2.48 | 1.10 | ||
461.00 | 4,889 Cr | 37.86 | 4.10 | 0.22 | 10.82 | 16.48 | 9.03 | ||
2933.65 | 4,827 Cr | 41.91 | 7.97 | 0.82 | 19.03 | 24.66 | 14.52 | ||
151.20 | 4,453 Cr | 32.35 | 2.48 | 0.66 | 7.65 | 10.29 | 5.32 | ||
1283.10 | 4,444 Cr | -60.10 | 6.41 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1630.05 | 4,023 Cr | 41.14 | 4.92 | 0.00 | 11.39 | 15.94 | 9.99 | ||
| Median: 7 Co. | — | 990.00 | 4,827 Cr | 39.22 | 4.92 | 0.21 | 10.82 | 14.30 | 7.67 |
